We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.00 | -0.51% | 1,356.50 | 1,356.00 | 1,356.50 | 1,370.00 | 1,353.00 | 1,365.00 | 5,013,886 | 16:29:58 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.41 | 56.52B |
From Jan 2020 to Jan 2025
By Sabela Ojea
GlaxoSmithKline PLC said Thursday that it has appointed Brian McNamara as the new chief executive designate of Consumer Healthcare Co., the company that will result from the proposed demerger of Consumer Healthcare from GSK in 2022.
The British pharmaceutical major said the separation of Consumer Healthcare will be made through a demerger in mid-2022 of at least 80% of GSK's holding to shareholders.
A formal process to appoint a chair and to form a board of directors for the new consumer health company is expected for the second half of the year, the London-listed company said.
"This new Board will include the appropriate mix of skills, experience, diversity and continuity, relevant to Consumer Health, to represent and maximize the value of this new business for shareholders," GlaxoSmithKline said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
July 22, 2021 10:15 ET (14:15 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
